Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: faseb journal + new drugs + new  Related to the article below (Last Update: 5/12/2008)

Researchers Discover Molecular Basis Of A Form Of Muscular Dystrophy
Science Daily (press release) - Apr 30, 2008
By targeting the cellular and molecular mechanisms responsible for creating this protein, scientists could develop new drugs to stop muscle wasting from ...
Chemotherapy drug reduction may be possible
Belleville News Democrat,  USA - Apr 29, 2008
"Many chemotherapeutic drugs have unwanted side effects," said Dr. Patrick M. Winter, the lead author of the new study. "We've shown that our nanoparticle ...

AFP
Muscular dystrophy type linked to missing protein: study
AFP - Apr 30, 2008
They hope the findings of their research will lead to the development of new treatments to stop muscle wasting from the disease, they said. ...
Nano-sized technology has super-sized effect on tumors
Washington University Record, MO - Apr 16, 2008
In an article published online in The FASEB Journal, the researchers describe a significant reduction of tumor growth in rabbits treated with nanoparticles ...
Fluorine-based nanoparticles on track to improve cancer detection ...
Nanowerk LLC, HI - Apr 18, 2008
In one of the new papers, published in The FASEB Journal ("Minute dosages of ανβ3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and ...
Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious ...
Earthtimes, UK - Apr 14, 2008
All pharmaceutical and biological drugs or devices that have been approved by the US Food and Drug Administration (FDA) for first or new indications in the ...
Systems Biology in the Study of Neurological Disorders: Focus on ...
RedOrbit, TX - Apr 30, 2008
Other studies using this strategy were aimed at exploring new drugs for AD treatment (Beher et al. 2002; Davies et al. 1999) or potential development of a ...

CTV.ca
Abdominal fat may make you hungrier, fatter: study
CTV.ca, Canada - Apr 17, 2008
In a study published in a recent edition of The FASEB Journal, scientists from the Lawson Health Research Institute, part of the University of Western ...
Your Belly Fat Could Be Making You Hungrier Science Daily (press release)
all 39 news articles »

In order to show you the most relevant results, we have omitted some entries very similar to the 8 already displayed.
If you like, you can repeat the search with the omitted results included.

Source: Google News

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic -
TD WARNER, JA MITCHELL - The FASEB Journal, 2004 - FASEB
... for increased risk of thrombotic events FASEB J, December 1 ... Home page, Journal of
the American Animal Hospital ... Drugs: Evidence for a New Mechanism Involving the ...

Aminoacyl tRNA synthetases as targets for new anti-infectives -
P Schimmel, J Tao, J Hill - The FASEB Journal, 1998 - FASEB
... (The FASEB Journal. 1998;12:1599-1609.) ? 1998 FASEB. REVIEWS. ... For this purpose,
aminoacyl tRNA synthetases are being pursued as targets for new drugs. ...

A New Drug-Screening Procedure for Photosensitizing Agents Used in Photodynamic Therapy for CNV -
N Lange, JP Ballini, G Wagnieres, H van den Bergh - Investigative Ophthalmology & Visual Science, 2001 - ARVO
... Ophthalmology, Inc. A New Drug-Screening Procedure for Photosensitizing
Agents Used in Photodynamic Therapy for CNV. Norbert Lange ...

Role of iron in anthracycline cardiotoxicity: new tunes for an old song? -
G MINOTTI, G CAIRO, E MONTI - The FASEB Journal, 1999 - FASEB
... (The FASEB Journal. 1999;13:199-212.) ? 1999 FASEB. Reviews. ... studies of the role
of C-13 hydroxy metabolites of anthracyclines have provided new perspectives on ...

A new role for neurotrophins: involvement of brain-derived neurotrophic factor and neurotrophin-4 in … -
VA BOTCHKAREV, NV BOTCHKAREVA, PIA WELKER, M METZ, … - The FASEB Journal, 1999 - FASEB
... (The FASEB Journal. 1999;13:395-410.) ? 1999 FASEB. ... Subramaniam, A., Bulfone-Paus,
S., Hagen, E., Braun, A., Lommatzsch, M., Renz, H., Paus, R. A new role for ...

The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory … -
G Minotti, S Recalcati, A Mordente, G Liberi, AM … - The FASEB Journal, 1998 - FASEB
... (The FASEB Journal. 1998;12:541-552.) ? 1998 FASEB. ... between aconitase and IRP-1.
These results may also provide a guideline to design new drugs that mitigate ...

The importance of being proline: the interaction of proline-rich motifs in signaling proteins with … -
BK Kay, MP Williamson, M Sudol - FASEB J, 2000 - FASEB
... (The FASEB Journal. 2000;14:231-241.) ? 2000 FASEB ... In particular, SH3, WW, and several
new protein-interaction domains prefer ligand sequences that are proline ...

COX-2 Inhibitors: A New Class of Antiangiogenic Agents -
JL MASFERRER, A KOKI, K SEIBERT - Annals of the New York Academy of Sciences, 1999 - Blackwell Synergy
... chemopreventive and antitumor activities observed for this new class of ... FASEB J.
11: 234?247 ... American Journal of Hematology 80:3, 169. Kosuke Shimizu, Tomohiro ...

Cyclooxygenase in biology and disease -
RN Dubois, SB Abramson, L Crofford, RA Gupta, LS … - FASEB J, 1998 - FASEB
... The FASEB Journal. 1998;12:1063-1073.) ? 1998 FASEB ... Rheumatology, New York University
School of Medicine, Hospital for Joint Diseases, New York, New York 10003 ...

The new frontier in muscular dystrophy research: booster genes -
EVA ENGVALL, UM WEWER - The FASEB Journal, 2003 - FASEB
... (The FASEB Journal. 2003;17:1579-1584.) ? 2003 FASEB The new frontier in muscular
dystrophy research: booster genes. EVA ENGVALL * ,1 and ULLA M. WEWER ...

Source: Google Scholar

New target for HIV/AIDS drugs and vaccines discovered
Article in The FASEB Journal shows how HIV delivers a one-two punch to cells of the innate immune system
Bethesda, MD--Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection. It has been known that HIV proteins disable the antibody-forming part of the immune system (the “homeland defense” or acquired immune system). In this report, researchers demonstrate for the first time how the HIV-1 Nef viral protein delivers a one-two punch to the body’s  innate immune system (our “early warning system” composed of dendritic and natural killer cells). First, Nef hijacks dendritic cells (DCs) to upset the function of natural killer (NK) cells. Second, after blocking this first line of defense against the immune system, Nef uses DCs and NK cells to create a microenvironment that actually makes it easier for HIV/AIDS to replicate.
According to Maria Giovanna Quaranta of Instituto Superiore de Sanità and first author of the article, “The findings described in this work may have several implications for AIDS treatment: the understanding of Nef function, mechanism of action, and cellular partners might aid the discovery of suitable drugs able to block the activity of this smart protein.” Quaranta added, “An exciting possibility is the design of a vaccine including a mutated Nef protein unable to assist the virus in the control of its host.”

The research findings also raise another intriguing possibility: Nef proteins may be able to boost or suppress DC and NK cell activity. If so, it may prove to be a valuable new therapeutic approach for people with diseases and disorders that involve overactive or underactive immune responses. DCs and NK cells play critical roles in the body’s initial defense against infection. DCs are instrumental in identifying foreign invaders to the body and then orchestrating an immune response that ultimately removes them. NK cells are among the first cells summoned by DCs to help isolate and contain the infection until more potent reinforcements can be manufactured to eradicate the virus or bacteria. When DC cells can no longer adequately “manage” the immune response and when NK cells can no longer contain infections, the likelihood of survival without medical intervention is relatively low.

“HIV’s relatively rapid evolution has given it an ability to handle all our bodies can throw at it and more,” said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal. “Now that we know how the viral protein disables the innate as well as the acquired arm of our immune system, we can begin to design decoy proteins or to devise new vaccines. Millions of lives depend on our finding a way to restore both aspects of our immune defense against HIV/AIDS—this study should go a long way toward that goal.”

The FASEB Journal is published by the Federation of American Societies for Experimental Biology (FASEB) and is consistently ranked among the top three biology journals worldwide by the Institute for Scientific Information. FASEB comprises 21 nonprofit societies with more than 80,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB advances biological science through collaborative advocacy for research policies that promote scientific progress and education and lead to improvements in human health.

###
FOR IMMEDIATE RELEASE

CONTACT:
Cody Mooneyhan
Managing Editor
Tel: 1-301-634-7104
E-mail: cmooneyhan@faseb.org
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.